Does CVS–Aetna Spell the End of Business as Usual?

The proposed $70 billion deal between CVS and Aetna would be a vertical merger that could heighten competition. By offering a new value proposition, the new company would aim to stay relevant despite encroachment by e-tailers and reduce total spending for care.

Uloženo v:
Podrobná bibliografie
Vydáno v:The New England journal of medicine Ročník 378; číslo 7; s. 593 - 595
Hlavní autor: Dafny, Leemore S
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Massachusetts Medical Society 15.02.2018
Témata:
Acquisitions & mergers
Antitrust
Drug stores
Health care policy
Market shares
Pharmaceutical industry
Pharmacy
Prescription drugs
Primary care
ISSN:0028-4793, 1533-4406, 1533-4406
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The proposed $70 billion deal between CVS and Aetna would be a vertical merger that could heighten competition. By offering a new value proposition, the new company would aim to stay relevant despite encroachment by e-tailers and reduce total spending for care.
Bibliografie:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Editorial-2
ObjectType-Commentary-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMp1717137